On Wednesday, the Food and Drug Administration (FDA) issued a statement granting additional exemptions from its November 27, 2024 deadline for compliance with certain product transaction requirements. The exemptions followed concerns from the stakeholders across the pharmaceutical supply chain about their ability to fully comply with the new requirements without significant impact to product distribution timelines….
By: Polsinelli
By: Polsinelli
